S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
Maria Cristina Pirosa(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jan Maciej Zaucha(Gdańsk Medical University), G. Bernhard(Institute of Oncology Research), Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Marcello Rodari(Humanitas University), Luigi Maria Larocca(Agostino Gemelli University Polyclinic), Luca Ceriani(St Thomas' Hospital), Joyce Marques de Almeida(Institute of Oncology Research), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), D. T. Martina(Humanitas University), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Antonio Pinto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Stasia(Institute of Oncology Research), F. Bergesio(Carle Foundation Hospital), Deborah Piffaretti(Institute of Oncology Research), Francesco Cavalli(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Simone Bocchetta(Institute of Oncology Research), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anastasios Stathis(Princess Margaret Cancer Centre), Katia Pini(Institute of Oncology Research), Matin Salehi(SIB Swiss Institute of Bioinformatics), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), Grzegorz Romanowicz(Gdańsk Medical University), S. Hohaus(Agostino Gemelli University Polyclinic), Gabriela Forestieri(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alden A. Moccia(BC Cancer Agency), C. Marco(Institute of Oncology Research), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), A. Rinaldi(Institute of Oncology Research), Armando Santoro(IRCCS Humanitas Research Hospital), Emanuele Zucca(Università della Svizzera italiana), Alessio Bruscaggin(Institute of Oncology Research), Valeria Spina(Ente Ospedaliero Cantonale), Salvatore Annunziata(Agostino Gemelli University Polyclinic)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791